Journal

eNeuro
ISSN: 2373-2822
Titre abrégé: eNeuro
Pays: United States
ID NLM: 101647362

Informations de publication

Date de publication:
04 2023
Historique:
received: 21 07 2022
revised: 09 12 2022
accepted: 13 12 2022
medline: 17 5 2023
pubmed: 18 4 2023
entrez: 17 4 2023
Statut: epublish

Résumé

In addition to brain disorders, which constitute a devastating consequence of prenatal alcohol exposure (PAE), eye development is also significantly affected. Given that the retina is a readily accessible part of the central nervous system, a better understanding of the impact of ethanol on retinal development might provide ophthalmological landmarks helpful for early diagnosis of fetal alcohol syndrome. This study aimed to provide a fine morphometric and cellular characterization of the development of retinal microvasculature and neurovascular interactions in a mouse model of fetal alcohol spectrum disorder (FASD). The data revealed that PAE impaired superficial vascular plexus development. In particular, progression of the vascular migration front was significantly decreased in PAE retinas, supporting a delay in plexus progression. Moreover, a significant decrease in the vessel density and number of perforating vessels was quantified in PAE mice, supporting less angiogenesis. The present study provides also the first evidence of a close interaction between migrating calretinin-positive interneurons and perforating microvessels in the inner nuclear layer of the developing retina. This neurovascular association was significantly impaired by PAE. Moreover, projections of amacrine cells were abnormally distributed and densified in stratum S1 and S2. In humans, comparison of a five-month-old control infant with a three-month-old alcohol-exposed case revealed a similar mispositioning of calretinin-positive interneurons. This opens new research avenues regarding a neurovascular contribution in the deleterious effects of alcohol in the developing retina and support that ophthalmological examination could become a promising approach for early detection of alcohol-exposed infants presenting with neurovascular brain defects.

Identifiants

pubmed: 37068950
pii: ENEURO.0295-22.2022
doi: 10.1523/ENEURO.0295-22.2022
pmc: PMC10135090
pii:
doi:

Substances chimiques

Calbindin 2 0
Ethanol 3K9958V90M

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 Dumanoir et al.

Déclaration de conflit d'intérêts

The authors declare no competing financial interests.

Auteurs

Marion Dumanoir (M)

Rouen Université Institut National de la Santé et de la Recherche Médicale Unité 1245, Genomic and Personalized Medicine in Cancer and Neurological Disorders, Institute for Research and Innovation in Biomedicine (IRIB), Normandie University, 76183, Rouen, France.

Anaïs Leroy (A)

Rouen Université Institut National de la Santé et de la Recherche Médicale Unité 1245, Genomic and Personalized Medicine in Cancer and Neurological Disorders, Institute for Research and Innovation in Biomedicine (IRIB), Normandie University, 76183, Rouen, France.

Delphine Burel (D)

Rouen Université Institut National de la Santé et de la Recherche Médicale Unité 1245, Genomic and Personalized Medicine in Cancer and Neurological Disorders, Institute for Research and Innovation in Biomedicine (IRIB), Normandie University, 76183, Rouen, France.
Regional Platform for Cell Imaging of Normandy (PRIMACEN), Institute for Research and Innovation in Biomedicine (IRIB), Rouen University, 76183, Rouen, France.

Annie Laquerrière (A)

Rouen Université Institut National de la Santé et de la Recherche Médicale Unité 1245, Genomic and Personalized Medicine in Cancer and Neurological Disorders, Institute for Research and Innovation in Biomedicine (IRIB), Normandie University, 76183, Rouen, France.
Department of Pathology, Rouen University Hospital, 76183, Rouen, France.

François Janin (F)

Rouen Université Institut National de la Santé et de la Recherche Médicale Unité 1245, Genomic and Personalized Medicine in Cancer and Neurological Disorders, Institute for Research and Innovation in Biomedicine (IRIB), Normandie University, 76183, Rouen, France.

Alexis Lebon (A)

Regional Platform for Cell Imaging of Normandy (PRIMACEN), Institute for Research and Innovation in Biomedicine (IRIB), Rouen University, 76183, Rouen, France.

Manon Valet (M)

Institut National de la Santé et de la Recherche Médicale Unité 1096, Laboratory EnVI, Normandie University, Rouen University, 76183, Rouen, France.

David Godefroy (D)

Rouen Université, Institut National de la Santé et de la Recherche Médicale Unité 1239, Neuronal and Neuroendocrine Differentiation and Communication Laboratory, Institute for Research and Innovation in Biomedicine (IRIB), Normandie University, Rouen University, 76183, Rouen, France.

Lauriane Przegralek (L)

Rouen Université Institut National de la Santé et de la Recherche Médicale Unité 1245, Genomic and Personalized Medicine in Cancer and Neurological Disorders, Institute for Research and Innovation in Biomedicine (IRIB), Normandie University, 76183, Rouen, France.

Maryline Lecointre (M)

Rouen Université Institut National de la Santé et de la Recherche Médicale Unité 1245, Genomic and Personalized Medicine in Cancer and Neurological Disorders, Institute for Research and Innovation in Biomedicine (IRIB), Normandie University, 76183, Rouen, France.

Serge Picaud (S)

Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Institut de la Vision, Sorbonne Université, 75006, Paris, France.

Stéphane Marret (S)

Rouen Université Institut National de la Santé et de la Recherche Médicale Unité 1245, Genomic and Personalized Medicine in Cancer and Neurological Disorders, Institute for Research and Innovation in Biomedicine (IRIB), Normandie University, 76183, Rouen, France.
Department of Neonatal Paediatrics and Intensive Care and Neuropaediatrics, Rouen University Hospital, 76183, Rouen, France.

Florent Marguet (F)

Rouen Université Institut National de la Santé et de la Recherche Médicale Unité 1245, Genomic and Personalized Medicine in Cancer and Neurological Disorders, Institute for Research and Innovation in Biomedicine (IRIB), Normandie University, 76183, Rouen, France.
Department of Pathology, Rouen University Hospital, 76183, Rouen, France.

Bruno J Gonzalez (BJ)

Rouen Université Institut National de la Santé et de la Recherche Médicale Unité 1245, Genomic and Personalized Medicine in Cancer and Neurological Disorders, Institute for Research and Innovation in Biomedicine (IRIB), Normandie University, 76183, Rouen, France.

Carole Brasse-Lagnel (C)

Rouen Université Institut National de la Santé et de la Recherche Médicale Unité 1245, Genomic and Personalized Medicine in Cancer and Neurological Disorders, Institute for Research and Innovation in Biomedicine (IRIB), Normandie University, 76183, Rouen, France carole.lagnel@univ-rouen.fr.
Department of Biochemistry, Rouen University Hospital, 76183, Rouen, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH